Acute myelogenous leukemia and aging: Clinical interactions

Hematology/Oncology Clinics of North America

Volumn 14, Issue 1, 2000, Pages 251-267

  Lancet, Jeffrey E ^a   Willman, Cheryl L ^b   Bennett, John M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; AGING; AUTOTRANSPLANTATION; CANCER PATIENT; HUMAN; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033950050     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70287-2     Document Type: Article

References (65)

1. R.J. Arceci Clinical significance of P-glycoprotein in multidrug resistance malignancies Blood 81 1993 2215
2. M. Baudard J.P. Marie M. Cadiou Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients Br J Haematol 86 1994 82
3. J.M. Bennett M.L. Young J.W. Andersen Long-term survival in acute myeloid leukemia Cancer S80 1997 2205
4. J.M. Bennett D. Catovsky M.T. Daniel Proposed revised criteria for the classification of acute myeloid leukemia Ann Intern Med 103 1985 620
5. A.G. Borg R. Burgess L.M. Green Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival Br J Haematol 103 1998 1083
6. T.R. Chauncey C. Rankin J.E. Anderson A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC833: Southwest Oncology Group Study #9617 Blood 92S1 1998 A945
7. K.V. Chin I. Pastan M.M. Gottesman Function and regulation of the human multidrug resistance gene Adv Cancer Res 60 1993 157
8. H. Dombret C. Chastang P. Fenaux A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia N Engl J Med 332 1995 1678
9. M. Extermann J. Overcash G.H. Lyman Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582
10. E.J. Feldman K. Seiter L. Damon A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia Leukemia 11 1997 485
11. P. Fenaux C. Preudhomme J.L. Lai Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases Br J Haematol 73 1989 61
12. F. Ferrara S. Mirto Serum LDH as a predictor of clinical outcome in acute myelogenous leukemia of the elderly Br J Haematol 92 1996 627
13. P.J. Fialkow J.W. Singer W.H. Raskind Clinical development, stem cell differentiation, and clinical remission in acute non lymphocytic leukemia N Engl J Med 317 1997 468
14. B. Gahn D. Haase M. Unterhalt De novo AML with dysplastic hematopoiesis: Cytogenetic and prognostic significance Leukemia 10 1996 946
15. G. Garcia-Manero D. Grosso F. Beardell Amifostine cytoprotection and dose escalation of idarubicin in elderly high risk patients with acute myelogenous leukemia Blood 92S1 1998 A3927
16. J.E. Godwin K.J. Kopecky D.R. Head A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031) Blood 91 1998 3607
17. F. Groves M. Linet S. Devesa Epidemiology of Leukemia G. Henderson M. Lister Greaves H. Leukemia ed 6 1996 WB Saunders Philadelphia 152
18. B. Heinemann U. Jehn Acute myeloid leukemia in the elderly: Biologic features and search for adequate treatment Ann Hematol 63 1991 179
19. A. Heyll C. Aul G. Gogolin Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia Ann Hematol 68 1994 279
20. International Bone Marrow Transplant Registry, Data from Statistical Center, 1994–1997.
21. G.H. Jackson P.R.A. Taylor A. Iqbal The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly: A report of toxicity and efficacy Leukemia 11 1997 1193
22. P.R.E. Johnson D.J. Ryder Liu Yin J.A. Validation of a model to predict survival in elderly patients with acute myeloid leukaemia Br J Haematol 90 1995 954
23. P.R.E. Johnson L.P. Hunt Liu Yin J.A. Prognostic factors in elderly patients with acute myeloid leukaemia: Development of a model to predict survival Br J Haematol 85 1993 300
24. S. Kato H. Muta J. Nishimura Absence of correlation between cytotoxicity and drug transport by P-glycoprotein in clinical leukemic cells Eur J Haematol 47 1991 146
25. H.G. Klingemann Role of postinduction immunotherapy in acute myeloid leukemia Leukemia 10S1 1996 S21
26. H.M. Lazarus W.R. Vogler C.P. Burns High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia Cancer 63 1989 1055
27. C.P. Leith K.J. Kopecky J. Godwin Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy. A Southwest Oncology Group Study Blood 89 1997 3323
28. F. Leoni S. Ciolli G. Giuliani Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: Pharmacokinetic study and clinical results Br J Haematol 90 1995 169
29. A.F. List K.J. Kopecky C.L. Willman Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study Blood 92S1 1998 A1281
30. A.F. List Role of multidrug resistance and its pharmacologic modulation in acute myeloid leukemia Leukemia 10 1996 937
31. A.F. List C.S. Spier T.M. Grogan Overexpression of the major vault transporter protein Lung-Resistance Protein predicts treatment outcome in acute myeloid leukemia Blood 87 1996 2464
32. Liu Yin J.A. P.R.E. Johnson J.M. Davies Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia Br J Haematol 79 1991 415
33. B. Lowenberg S. Duciu E. Archimbaud Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy–the value of low dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9 J Clin Oncol 16 1998 872
34. B. Lowenberg S. Suciu E. Archimbaud Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON) Blood 90 1997 2952
35. B. Lowenberg R. Zittoun H. Kerkhofs On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group J Clin Oncol 7 1989 1268
36. A. Manoharan R.I. Baker P.W. Kyle Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach Am J Hematol 55 1997 115
37. J.P. Marie R. Zittoun B.I. Sikic Multidrug resistance ( mdr 1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity Blood 78 1991 586
38. F. Marmont B. Allione E. Audisio The significance of the achievement of complete response in elderly patients with acute myeloblastic leukemia Ann Oncol 9S3 1998 A070
39. R.J. Mayer R.B. Davis C.A. Schiffer Intensive postremission chemotherapy in adults with acute myeloid leukemia N Engl J Med 331 1994 896
40. G. Palka G. Calabrese G. Fiortoni Cytogenetic survey of 80 patients with acute nonlymphocytic leukemia Cancer Genet Cytogenet 59 1992 45
41. J. Pedersen-Bjergaard P. Philip Olesen Larsen S. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series Leukemia 7 1990 1975
42. J. Pedersen-Bjergaard P. Philip Olesen Larsen S. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia Blood 76 1990 1083
43. B.A. Peterson C.D. Bloomfield Treatment of acute nonlymphocytic leukemia in elderly patients Cancer 40 1977 647
44. R. Pirker J. Wallner K. Geissler MDR1 gene expression and treatment outcome in acute myeloid leukemia J Natl Cancer Inst 83 1991 708
45. J.K.H. Rees D. Swirsky R.G. Gray Principal results of the medical research council's 8th acute myeloid leukaemia trial Lancet 2 1986 1236
46. J. Reiffers F. Huguet A.M. Stoppa A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55–75 Leukemia 10 1996 389
47. L. Repetto A. Venturino M. Vercelli Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions Cancer 82 1998 760
48. L.A.G. Ries C.L. Kosary B.F. Hankey SEER Cancer Statistics Review, 1973–1994 1997 National Cancer Institute Bethesda, MD NIH Pub. No 97-2789.
49. J.M. Rowe D. Neuberg W. Friedenberg A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group (E3993) Blood 92S1 1998 A1284
50. J.M. Rowe J.W. Andersen J.J. Mazza A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490) Blood 86 1995 457
51. J.D. Rowley G. Alimena O.M. Garson A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype Blood 59 1982 1013
52. D.P. Sandler Epidemiology of acute myelogenous leukemia Semin Oncol 14 1987 359
53. 1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia Br J Haematol 75 1990 340
54. E. Schneider K.H. Cowan H. Bader Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 85 1995 186
55. U. Schuler U. Schakel G. Wandt Treatment of acute myelogenous leukemia in the elderly with daunorubicin + ara-c combined with amifostine—Results of a pilot study Blood 92S1 1998 A4245
56. R. Stasi A. Venditti Del Poeta G. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia. Analysis of prognostic factors Cancer 77 1996 2476
57. R.S. Stein W.R. Vogler E.F. Winton Therapy of acute myelogenous leukemia in patients over the age of 50: A randomized Southeastern Cancer Study Group Trial Leuk Res 14 1990 895
58. R.M. Stone D.T. Berg S.L. George Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia N Engl J Med 332 1995 1671
59. P.R.A. Taylor M.M. Reid A.N. Stark De novo acute myeloid leukaemia in patients over 55-years-old: A population-based study of incidence, treatment, and outcome Leukemia 9 1995 231
60. + acute myeloid leukemia cells Blood 82 1993 3157
61. Uyl-de Groot C.A. B. Lowenberg E. Vellenga Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia Br J Haematol 100 1998 629
62. C.L. Willman Molecular genetic features of myelodysplastic syndromes (MDS) Leukemia 12S1 1998 S2
63. C.L. Willman The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program Semin Hematol 34 1997 25
64. C.L. Willman Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR1) Leukemia 10S1 1996 S33
65. R. Yancik Cancer burden in the aged. An epidemiologic and demographic overview Cancer 80 1997 1273